<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01735812</url>
  </required_header>
  <id_info>
    <org_study_id>ICUFL-01</org_study_id>
    <nct_id>NCT01735812</nct_id>
  </id_info>
  <brief_title>Laparoscopic Cryoablation of Uterine Fibroids</brief_title>
  <acronym>UFREEZE-01</acronym>
  <official_title>Cryoablation of Symptomatic Uterine Fibroids Using the IceSense3™ System in a Percutaneous Laparoscopic-assisted Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IceCure Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IceCure Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the safety &amp; efficacy of cryoablation using IceCure
      medical's IceSense3™ device for the treatment of symptomatic uterine fibroids in a
      percutaneous lap-assisted approach.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in patient's fibroid-related quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate procedural efficacy by the improvement in patient's fibroid-related quality of life as assessed in scores of symptom severity subscale questionnaire (SSS-UFS-QOL) at 12 months post-treatment comparing to baseline score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, subsequent interventions and procedure-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate procedural safety by monitoring incidence, subsequent interventions and procedure-related adverse events within 12 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in fibroid volume</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction in fibroid volume as measured by US/MRI imaging at 6 and 12 months follow-up post treatment comparing to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in menstrual bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in menstrual bleeding compared to baseline as measured in chemical analysis (Alkaline haematin technique) at 6 and 12 months post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in patient's fibroid-related quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Improvement in patient's fibroid-related quality of life as assessed in scores of symptom severity subscale questionnaire (SSS-UFS-QOL) at 6 months post-treatment comparing to baseline score.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient's and physician's overall treatment evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Patient's and physician's overall treatment evaluation and satisfaction will be assessed using a self-report questionnaire at 6 and 12 months post treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient blood loss</measure>
    <time_frame>12 months</time_frame>
    <description>Patient blood loss will be also evaluated by Hemoglobin (Hb) level measurements at 6 and 12 months post treatment and will be compared to baseline.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Symptomatic Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>symptomatic UF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IceSense3 system</intervention_name>
    <description>The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.</description>
    <arm_group_label>symptomatic UF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pre-menopausal woman between the ages of 30 and 50 (inclusive)

          2. Patient had completed her family planning and does not desire future childbearing.

          3. Patient is suffering from menorrhagia as a result of symptomatic uterine fibroids.

          4. Patient's uterus size is smaller than 18 gestational weeks.

          5. Patient wishes to preserve her uterus and avoid hysterectomy.

          6. Patient has 1-3 treatable uterine fibroids in size of up to 10cm measured by US/MRI.

          7. Overall treated fibroid volume is ≤ 3,138cm3 (width x length x height x 0.523)

          8. Patient has clinical menorrhagia as indicated by menstrual blood loss of ≥160 ml
             during one baseline cycle prior to treatment.

          9. Patient is able to visit the clinic as needed during the 1 year follow-up period
             following the treatment.

         10. The patient has been informed of the study and agrees to its provisions, and has
             signed an IRB approved written informed consent, including data privacy authorization.

        Exclusion Criteria:

          1. Patient had not finished her family planning

          2. Patient was already treated for uterine fibroids in the past (UAE, myomectomy, HIFU,…)
             or undergone endometrial ablation.

          3. Patient had been treated with GnRH over the last 3 months.

          4. Patient has known symptomatic endometriosis that cannot be completely removed during
             laparoscopic procedure.

          5. Patient has known or suspected adenomyosis

          6. Patient had any active abdominal/pelvic inflammatory disease.

          7. Patient has known or suspected gynecologic malignancy.

          8. Patient with submucosal fibroids type &quot;zero&quot;

          9. Patient with undiagnosed vaginal bleeding

         10. Patient with blood clotting disorders

         11. Patients carrying contagious diseases such as Tuberculosis Hepatitis or AIDS.

         12. Patient participating in other trials using drugs or devices.

         13. Patient is unable to commit all study requirements including follow-up visits and
             questionnaires.

         14. Patient has any contraindication for laparoscopic surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moty Pansky, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf Harofe Hospital, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Sadka, Mrs</last_name>
    <phone>972 4 623 0333</phone>
    <phone_ext>223</phone_ext>
    <email>Elisabeth@Icecure-medical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf Harofe</name>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moty Pansky, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Moty Pansky, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2012</study_first_posted>
  <last_update_submitted>February 5, 2015</last_update_submitted>
  <last_update_submitted_qc>February 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cryoablation</keyword>
  <keyword>uterine fibroid</keyword>
  <keyword>uterine myoma</keyword>
  <keyword>who completed her family planning</keyword>
  <keyword>but wishes to preserve her uterus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

